Our guts are home to trillions of bacteria, and research over the last few decades has established how essential they are to our physiology – in health and disease.
FDA is poised to pull Ocaliva as adcomm documents question post-approval study results
The FDA appeared ready to pull its accelerated approval of Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, bluntly laying out its rationale in
September 12, 2024